Plasmid DNA Production for Therapeutic Applications
Plasmid DNA (pDNA) is the base for promising DNA vaccines and gene therapies against many infectious, acquired, and genetic diseases, including HIV-AIDS, Ebola, Malaria, and different types of cancer, enteric pathogens, and influenza. Compared to conventional vaccines, DNA vaccines have many advantages such as high stability, not being infectious, focusing the immune response to only those antigens desired for immunization and long-term persistence of the vaccine protection. Especially in developing countries, where conventional effective vaccines are often unavailable or too expensive, there is a need for both new and improved vaccines. Therefore the demand of pDNA is expected to rise significantly in the near future. Since the injection of pDNA usually only leads to a weak immune response, several milligrams of DNA vaccine are necessary for immunization protection. Hence, there is a special interest to raise the product yield in order to reduce manufacturing costs. In this chapter, the different stages of plasmid DNA production are reviewed, from the vector design to downstream operation options. In particular, recent advances on cell engineering for improving plasmid DNA production are discussed.
- Real-Time Observation of G-Quadruplex Dynamics Using Single-Molecule FRET Microscopy
- Obtaining Accurate Translations from Expressed Sequence Tags
- DNA Probes for FISH Analysis of C-Negative Regions in Human Chromosomes
- Candidate Diseases for Prenatal Gene Therapy
- DNA Extraction from Fossil Eggshell
- Selection of Primers for Polymerase Chain Reaction
- Separating and Analyzing Sulfur-Containing RNAs with Organomercury Gels
- Pyrosequencing Applications
- RNA Refolding Studied by Light-Coupled NMR Spectroscopy
- Fluorescence In Situ Hybridization for the Detection of Chromosome Aberrations and Aneuploidy Induced by Environmental Toxicants